Breaking News

AbbVie Breaks Ground on $233M Expansion of Singapore Manufacturing Facility

Will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network.

Author Image

By: Charlie Sternberg

Associate Editor

Earlier this week, AbbVie strengthened its manufacturing capabilities by breaking ground on a new $223 million expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s global network. About the Singapore Plant Located in Singapore’s Tuas Biomedical Park, AbbVie’s Singapore plant is a small-molecule and biologics manufacturing facility serving markets worldwide. This new investmen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters